Join industry leaders from @Curi_Bio @G2Gconsulting GCWC Capital, @HSBC and @lakestreetcm for insightful sessions focused on the life science fundraising landscape. Register for our October 27 Greater LA CEO Summit today: bit.ly/4xHAxhP #BiocomCEOSummit

A mentor’s experience can change the trajectory of an aspiring professional's career. The transition from college into the life science industry is a defining moment, and having dedicated guidance can make a meaningful difference. Through @BiocomInstitute's Life Science Career Fellowship program, mentors have the opportunity to guide emerging talent as they take their initial steps into the workforce. In our 2026 cohort, the percentage of fellows reporting strong confidence in pursuing life science careers jumped from 39% to 86%, while 95% of mentors agreed that fellows left the program fully prepared to seize new opportunities in the industry. With a flexible, six-month hybrid commitment totaling just 15 hours from January through June, mentoring offers a meaningful way to strengthen leadership skills, gain fresh perspectives and help build California’s life science workforce. Register to help guide the industry's rising talent: bit.ly/4d1P1Bw

AI is moving from experiment to operating model across life science. While 85% of surveyed organizations expect to increase agentic AI investment, only 22% report successfully scaling AI today. The next phase will be defined not by who experiments with AI, but by who can translate it into meaningful scientific and operational results. Explore the forces shaping California life science in Biocom’s 2026 Life Science Economic Impact Report: bit.ly/4uXG7uN

A therapy that works at the bench still has to be manufacturable. GeneFab CEO Philip Lee, Ph.D., discusses why scale should be considered early, how synthetic biology is changing the CDMO model and what’s ahead for in vivo therapies. Meet GeneFab and explore why designing for scale starts long before the manufacturing stage: bit.ly/4yfODbj

Partnering is officially open for @MedTechCon Hosted by @AdvaMedUpdate on October 18 – 21, this conference brings together more than 4,000 executives, innovators, investors, clinicians, regulators and policy leaders from 40+ countries. With 1,800+ companies represented, partnering gives you the opportunity to identify potential investors, customers, collaborators and strategic partners in Boston before you arrive. Register now to secure your spot and start scheduling one-on-one meetings before calendars fill up: bit.ly/4ykCy4v #MTC26 #medtech #MTC26HostPartner

This week in Bay Area life sciences: @ElixirMed receives regulatory approval in Japan for the DynamX Coronary Bioadaptor System. @RevMedicines receives FDA breakthrough therapy designation for daraxonrasib in combination with chemotherapy for first-line metastatic pancreatic cancer. #SantaAnaBio doses the first subjects in a Phase 1 study of SAB01 for the treatment of autoimmune inflammatory diseases. @TenayaThera receives FDA RMAT designation for TN-401 in PKP2-associated arrhythmogenic right ventricular cardiomyopathy. Subscribe to receive the next newsletter in your inbox: bit.ly/40rlR8a

Explore where AI is having meaningful impact across biotech at our San Diego CEO Summit on October 8. Learn how leading organizations are using AI to accelerate drug development, improve efficiency and compress timelines across R&D, clinical development and enterprise operations. Register here: bit.ly/3TPZKZl

Step away from the lab and join us for the 2026 @fishersci New Technology Show on Wednesday, September 30, at 11:00 a.m. at The Forum in South San Francisco. Explore breakthrough instruments and technologies from 35+ leading laboratory suppliers, connect directly with product specialists and discover new solutions to streamline your workflows. Lunch will be provided during the show, followed immediately by a happy hour hosted by Biocom. Reserve your spot today: bit.ly/3VahxLb

This month in Greater Los Angeles life sciences: @GileadSciences reports that its non-virology pipeline across oncology and inflammatory diseases has officially reached "critical mass" in research allocation. @Amgen announces Phase 3 DeLLphi-305 results for IMDELLTRA in combination with durvalumab in first-line extensive-stage small cell lung cancer. #ArmataPharmaceuticals receives FDA breakthrough therapy designation for AP-SA02. #DualitasTherapeutics enters a multi-year research collaboration with Roche to discover bispecific antibodies for autoimmune and inflammatory disorders. Subscribe to receive the next newsletter in your inbox: bit.ly/3WFbOLh

This week in San Diego life sciences: @Hologic partners with The White Dress Project to bring fibroid education and patient voices to the Empowerment Experience. @bhtherapeutics presents updated Phase 1/2 SOLARA trial data demonstrating encouraging anti-tumor activity for BH-30643 in EGFR C797S-positive non-small cell lung cancer. @carlsmed files a patent infringement lawsuit against DeGen Medical. @VivoSimSolana presents new NAMkind drug toxicity data demonstrating predictive superiority in liver and gastrointestinal safety across small molecules and ADCs. Subscribe to receive the next newsletter in your inbox: bit.ly/4iqn5b1